Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› PDAC
Clinical trial register · United States · industry-sponsored

PDAC Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
Arizona 8 Florida 8 Massachusetts 6 California 5 Colorado 5
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

PDAC trials in the USA

10 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Revolution Medicines, Inc.
Phase 3
400
Arizona, Florida, Minnesota
2026-08-28
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-05-22
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2025-12-15
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
Revolution Medicines, Inc.
Phase 1/2
1,130
Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts
2024-05-24
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/pdac

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition PDAC.

How many PDAC trials are recruiting in the US?

9 of the 10 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (PDAC), 10 studies
PhaseStudiesRecruitingShare
Phase 36560%
Phase 1/22220%
Phase 11110%
Phase 2/31110%

Most active sponsors

Lead sponsors with the most studies (PDAC)
Lead sponsorStudiesRecruiting
Revolution Medicines, Inc.65
AbbVie11
Adcendo ApS11
Immuneering Corporation11
Tango Therapeutics, Inc.11

Top states

Top states (PDAC), by number of studies with a site there
StateStudies
Arizona8
Florida8
Massachusetts6
California5
Colorado5
Connecticut5
Illinois5
Maryland4
Georgia3
Minnesota3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.